MedTrace Logo

RESECT: Improving Quality in TURBT Surgery.

NCT05154084 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19505

Last updated 2023-11-14

No results posted yet for this study

Summary

Superficial bladder cancer, known as non-muscle-invasive bladder cancer (NMIBC), is the most common type of bladder cancer. It is expensive to manage and significantly impacts on patients' quality of life. This is because there is a high burden of recurrent disease after initial treatment, and need for long term surveillance for recurrence.

The most important step in the diagnosis and treatment of NMIBC is the first surgical procedure called the transurethral resection of bladder tumour (TURBT). There is evidence that the quality of the TURBT operation, and the use of a single administration of bladder chemotherapy following the operation, can reduce cancer recurrence rates and progression to more invasive cancer. There is anecdotal evidence that the quality of TURBT surgery and the usage of intravesical chemotherapy varies widely between hospitals and thus may result in worse outcomes for some patients.

The primary objective of the study is to determine if audit and feedback can improve the quality of TURBT surgery and if this reduces recurrence of NMIBC.

Conditions

Interventions

BEHAVIORAL

Performance feedback and education

Hospitals and surgeons will have an online interactive performance feedback dashboard provided to them along with educational components.

Sponsors & Collaborators

  • Action Bladder Cancer UK

    collaborator OTHER

  • British Journal of Urology International

    collaborator UNKNOWN

  • Rosetrees Trust

    collaborator OTHER

  • Photocure

    collaborator INDUSTRY

  • KARL STORZ Endoscopy-America, Inc.

    collaborator INDUSTRY

  • University College, London

    collaborator OTHER

  • University of Aberdeen

    collaborator OTHER

  • The Urology Foundation, United Kingdom

    collaborator UNKNOWN

  • British Urology Researchers in Surgical Training

    lead OTHER

Principal Investigators

  • Veeru Kasivisvanathan, MBBS · University College, London

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-19
Primary Completion
2023-07-31
Completion
2023-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05154084 on ClinicalTrials.gov